Answers are grounded in this paper and cite their sources.
A new orally active antifungal agent, terbinafine, was used in the treatment of tinea pedis ('dry type' or moccasin type) and tinea manuum. Fifty-three adults over the age of 16 years with fungal infections of the feet and/or hands were treated with either oral terbinafine, 250 mg, or placebo, once daily for 2 weeks. The diagnosis of fungal infection was confirmed by examination of skin scrapings by microscopy and culture. Of these, 28 patients were evaluable for efficacy. At 8 weeks, 12 out of 14 (86%) patients who received terbinafine were mycologically negative (microscopy and culture) compared to one out of 14 (7%) patients on placebo (P less than 0.001, Fishers exact test, one-sided). At the end of the study 71% of patients in the terbinafine group were judged to have received effective therapy compared to 0% in the placebo group (P less than 0.001). Terbinafine was well tolerated, and more side-effects were seen in the placebo group.
No takes yet. Share an insight, caveat, or question.
White et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: